On July 21, 2026, Agios Pharmaceuticals Inc AGIO experienced a significant decline of 13%, trading at $34.75, following the release of topline results from its tebapivat clinical trial. The news has stirred reactions among investors, leading to the stock’s downward movement in the market.
- Market Cap: $2.38 billion
- GF Score™: 47/100, indicating average performance relative to peers
- Insider Activity: Sold $0.2 million in shares over the past three months
What’s Behind the News?
The recent drop in Agios Pharmaceuticals’ stock price is attributed to the disappointing topline results from its tebapivat clinical trial. This trial is pivotal for the company as it seeks to develop treatments for rare diseases, particularly in the field of hematology. The outcomes of such clinical trials are crucial, as they can significantly impact investor confidence and the company’s future prospects in a highly competitive biotechnology sector.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on developing differentiated medicines for rare diseases, particularly those related to cellular metabolism. With a market capitalization of approximately $2.38 billion, Agios operates within the healthcare sector and specializes in biotechnology. The company is known for its innovative product candidates, including Pyrukynd (mitapivat) and tebapivat, aimed at treating hemolytic anemias and other blood disorders.
How Is AGIO Valued?
Currently, GF Value™ data is not available for Agios Pharmaceuticals. However, the company’s price-to-sales (P/S) ratio stands at 35.41, indicating that investors are willing to pay a premium for each dollar of sales, which is typical in the biotechnology sector where future growth potential is often factored into valuations. The company’s price has fluctuated significantly over the past year, with a 52-week low of $22.24 and a high of $46.00. For more detailed information, visit the AGIO stock page.
What Does AGIO’s GF Score™ Tell Us?
The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021).
| GF Score™ | 47 |
| Financial Strength | 7/10 |
| Profitability | 1/10 |
| Growth | N/A |
| Valuation | N/A |
| Momentum | N/A |
Agios Pharmaceuticals has a GF Score™ of 47, indicating that it is performing at an average level compared to its peers. The company shows a strong financial strength score of 7/10, suggesting stability in its financial position. However, its profitability rank is concerning at 1/10, reflecting challenges in generating profits. This combination of strengths and weaknesses highlights the speculative nature of investing in Agios Pharmaceuticals. For further insights, visit the AGIO stock page.
What Are Insiders Doing with AGIO Stock?
In the past three months, insider activity has shown a net selling trend, with insiders selling a total of $0.2 million worth of shares. This trend may raise concerns among investors regarding the confidence of those within the company about its future performance.
What This Means for Investors
The recent decline in AGIO’s stock price, coupled with the disappointing clinical trial results, suggests caution for potential investors. While the company maintains a strong financial position, its profitability issues and insider selling activity may warrant a careful evaluation before making investment decisions. For the complete analysis, visit the AGIO stock page. You can also use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is AGIO’s GF Score™?
AGIO’s GF Score™ is 47/100, indicating average performance relative to its peers in the biotechnology sector.
How is AGIO valued?
AGIO’s price-to-sales (P/S) ratio is 35.41, reflecting a premium valuation typical for biotech companies focused on future growth.
What is AGIO’s P/E ratio compared to historical?
AGIO does not have a P/E ratio available due to negative earnings, which highlights the company’s ongoing profitability challenges.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].